Free Trial
NASDAQ:NVUS

Novus Therapeutics (NVUS) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$2.47
$2.67
50-Day Range
$9.85
$16.50
52-Week Range
$4.50
$27.32
Volume
53,779 shs
Average Volume
78,851 shs
Market Capitalization
$3.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
NVUS stock logo

About Novus Therapeutics Stock (NASDAQ:NVUS)

Novus Therapeutics, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.

NVUS Stock News Headlines

Vivoryon Therapeutics NV VVY
Viking Therapeutics Inc
I’m giving you the name of this investment for free
This key unlocks a new pathway to wealth that has been kept hidden from you for decades. In my new documentary I will provide you with all the details of this one-of-a-kind investment.
CYT Cyteir Therapeutics, Inc.
I’m giving you the name of this investment for free
This key unlocks a new pathway to wealth that has been kept hidden from you for decades. In my new documentary I will provide you with all the details of this one-of-a-kind investment.
East Career Technical Academy
Las Vegas Academy of the Arts
Perspective Therapeutics Inc
See More Headlines
Receive NVUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/16/2020
Today
7/15/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:NVUS
Fax
N/A
Employees
7
Year Founded
N/A

Profitability

Net Income
$-16,010,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$13.13 per share

Miscellaneous

Free Float
N/A
Market Cap
$3.65 million
Optionable
Not Optionable
Beta
2.07
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Jon S. Kuwahara CPA (Age 55)
    CPA, SVP of Fin. & Admin., Principal Financial Officer and Principal Accounting Officer
    Comp: $295.72k
  • Mr. Gregory J. Flesher (Age 50)
    Consultant
    Comp: $482.13k
  • Dr. David-Alexandre C. Gros M.D. (Age 48)
    CEO & Non Independent Director
  • Dr. Steven N. Perrin Ph.D. (Age 55)
    Pres, Chief Scientific Officer & Non Independent Director

NVUS Stock Analysis - Frequently Asked Questions

How were Novus Therapeutics' earnings last quarter?

Novus Therapeutics, Inc. (NASDAQ:NVUS) issued its earnings results on Monday, November, 16th. The biopharmaceutical company reported ($5.51) earnings per share for the quarter, missing analysts' consensus estimates of ($1.64) by $3.87.
Read the conference call transcript
.

When did Novus Therapeutics' stock split?

Novus Therapeutics shares reverse split before market open on Monday, October 5th 2020. The 1-18 reverse split was announced on Friday, October 2nd 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 2nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

What other stocks do shareholders of Novus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Novus Therapeutics investors own include Tonix Pharmaceuticals (TNXP), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), CymaBay Therapeutics (CBAY), Novavax (NVAX) and Geron (GERN).

This page (NASDAQ:NVUS) was last updated on 7/15/2024 by MarketBeat.com Staff

From Our Partners